Home / NKGN : OTC

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does NKGN make money? Does NKGN have pricing power? What's the Earnings Whisper? Will NKGN profit more as the business scales? What is NKGN's management track record? Is NKGN's current price justified?

NKGen Biotech, Inc. Common Stock

$0 -$0.05 (-95.80%)

OTC · 09 Sep 2026 18:54 UTC

Previous Close

Day Range

$0 - $0

Year Range

$0$0.77

Market Cap

274.26K

AVG Volume

4.56K

Trailing/Forward PE

-0/-

PEG ratio

-0

Dividend Yield

Next Earnings Date

Primary Exchange

Other OTC

Revenue (USD)

NKGN Revenue (USD) by year
Period	Revenue (USD)
2024	652K
2023	0
2022	3K
2021	0

Net Income (USD)

NKGN Net Income (USD) by year
Period	Net Income (USD)
2024	-44.29M
2023	-82.95M
2022	-6.96M
2021	-990.64K

Operating Income (USD)

NKGN Operating Income (USD) by year
Period	Operating Income (USD)
2024	-26.97M
2023	-29.74M
2022	-13.95M
2021	-2.51M

EBITDA (USD)

NKGN EBITDA (USD) by year
Period	EBITDA (USD)
2024	1.31M
2023	-81M
2022	-13.34M
2021	-2.51M

Cash Flows (USD)

NKGN Cash Flows (USD) by year
Period	Cash Flows (USD)
2024	-20.88M
2023	-22M
2022	-6.47M
2021	-1.52M

EPS (USD)

NKGN EPS (USD) by year
Period	EPS (USD)
2024	-1.54
2023	-4.11
2022	0.21
2021	-0.04

Expenses (USD)

NKGN Expenses (USD) by year
Period	Expenses (USD)
2024	27.29M
2023	29.77M
2022	13.85M
2021	2.32M

Cash & Debt (USD)

NKGN Cash & Debt (USD) by year
Period	Cash & Debt (USD)
2024	0
2023	26K
2022	117K
2021	1.72M

Debt ratios

NKGN Debt ratios by year
Period	Debt ratios
2023	0
2022	0.01
2021	0.91

Margins

NKGN Margins by year
Period	Margins
2024	50%
2022	-400%

Return on Capital

NKGN Return on Capital by year
Period	Return on Capital
2023	141.34%
2022	-445.09%
2021	-0.62%

Shares Outstanding

NKGN Shares Outstanding by year
Period	Shares Outstanding
2024	28.83M
2023	21.89M
2022	21.45M
2021	21.45M

Book Value Per Share (USD)

NKGN Book Value Per Share (USD) by year
Period	Book Value Per Share (USD)
2024	0
2023	-2.68
2022	0.07
2021	7.49

Total Assets (USD)

NKGN Total Assets (USD) by year
Period	Total Assets (USD)
2024	24K
2023	16.48M
2022	16.33M
2021	174.19M

Employee Count

NKGN Employee Count by year
Period	Employee Count
2024	26
2023	63

PE Ratio

NKGN PE Ratio by year
Period	PE Ratio
Dec 22	21.22
Dec 22	21.18
Dec 22	21.22
Dec 22	21.24
Nov 22	21.24
Nov 22	21.15
Nov 22	21.09
Nov 22	21.09
Oct 22	20.96
Oct 22	20.92
Oct 22	20.9
Oct 22	20.9
Sep 22	20.83
Sep 22	200.11
Sep 22	199.5
Sep 22	199.5
Sep 22	198.88
Aug 22	199.09
Aug 22	199.9
Aug 22	199.9
Aug 22	200.11
Jul 22	200.11
Jul 22	199.7
Jul 22	199.7
Jul 22	199.7
Jul 22	199.29

Free Cash Flow Yield

NKGN Free Cash Flow Yield by year
Period	Free Cash Flow Yield
Sep 26	-32536.8%
Sep 26	-34163.64%
Aug 26	-34163.64%
Aug 26	-13665.46%
Aug 26	-13665.46%
Aug 26	-13665.46%
Jul 26	-6832.73%
Jul 26	-1138.79%
Jul 26	-1138.79%
Jul 26	-1138.79%
Jul 26	-1138.79%
Jun 26	-1138.79%
Jun 26	-1138.79%
Jun 26	-1138.79%
Jun 26	-1138.79%
May 26	-1138.79%
May 26	-1138.79%
May 26	-1138.79%
May 26	-854.09%
May 26	-1138.79%
Apr 26	-1138.79%
Apr 26	-1138.79%
Apr 26	-1138.79%
Apr 26	-1138.79%
Mar 26	-1138.79%
Mar 26	-455.52%
Mar 26	-1138.79%
Mar 26	-341.64%
Feb 26	-1138.79%
Feb 26	-1138.79%
Feb 26	-1138.79%
Feb 26	-1138.79%
Jan 26	-1138.79%
Jan 26	-1138.79%
Jan 26	-1207.12%
Jan 26	-1207.12%
Jan 26	-1448.54%
Dec 25	-1316.86%
Dec 25	-1448.54%
Dec 25	-1957.49%
Dec 25	-1957.49%
Nov 25	-2011.86%
Nov 25	-3448.91%
Nov 25	-3448.91%
Nov 25	-3621.36%
Oct 25	-3621.36%
Oct 25	-3621.36%
Oct 25	-3621.36%
Oct 25	-36213.57%
Oct 25	-358733.48%
Sep 25	-652.24%
Sep 25	-541.48%
Sep 25	-541.48%
Sep 25	-503.49%
Aug 25	-539.45%
Aug 25	-541.48%
Aug 25	-512.48%
Aug 25	-512.48%
Aug 25	-512.48%
Jul 25	-377.61%
Jul 25	-298.94%
Jul 25	-239.08%
Jul 25	-239.16%
Jun 25	-298.7%
Jun 25	-286.99%
Jun 25	-217.41%
Jun 25	-211.02%
May 25	-254.42%
May 25	-247.57%
May 25	-205.11%
May 25	-419.57%
May 25	-564.49%
Apr 25	-529.5%
Apr 25	-562.72%
Apr 25	-623.34%
Apr 25	-398.59%
Mar 25	-439.36%
Mar 25	-462.29%
Mar 25	-422.54%
Mar 25	-355.01%
Feb 25	-134.48%
Feb 25	-125.98%
Feb 25	-113.7%
Feb 25	-167.75%
Jan 25	-146.87%
Jan 25	-138.88%
Jan 25	-162.99%
Jan 25	-146.72%
Jan 25	-104.25%
Dec 24	-125.03%
Dec 24	-139.35%
Dec 24	-178.44%
Dec 24	-203.43%
Nov 24	-222.96%
Nov 24	-254.82%
Nov 24	-337.95%
Nov 24	-331.54%
Nov 24	-333.78%
Oct 24	-223.41%
Oct 24	-223.08%

Price to Sales

NKGN Price to Sales by year
Period	Price to Sales
Sep 26	0.09
Sep 26	0.09
Aug 26	0.09
Aug 26	0.22
Aug 26	0.22
Aug 26	0.22
Jul 26	0.44
Jul 26	2.65
Jul 26	2.65
Jul 26	2.65
Jul 26	2.65
Jun 26	2.65
Jun 26	2.65
Jun 26	2.65
Jun 26	2.65
May 26	2.65
May 26	2.65
May 26	2.65
May 26	3.54
May 26	2.65
Apr 26	2.65
Apr 26	2.65
Apr 26	2.65
Apr 26	2.65
Mar 26	2.65
Mar 26	6.63
Mar 26	2.65
Mar 26	8.84
Feb 26	2.65
Feb 26	2.65
Feb 26	2.65
Feb 26	2.65
Jan 26	2.65
Jan 26	2.65
Jan 26	2.65
Jan 26	2.65
Jan 26	2.21
Dec 25	2.43
Dec 25	2.21
Dec 25	1.64
Dec 25	1.64
Nov 25	1.59
Nov 25	0.93
Nov 25	0.93
Nov 25	0.88
Oct 25	0.88
Oct 25	0.88
Oct 25	0.88
Oct 25	0.09
Dec 23	15367.65
Dec 23	18845
Dec 23	19069.35
Dec 23	18957.18
Nov 23	16433.29
Nov 23	15704.17
Nov 23	16377.21
Nov 23	17106.33
Oct 23	19798.47
Oct 23	16769.81
Oct 23	16825.9
Oct 23	19630.21
Sep 23	46551.65
Sep 23	68359.98
Sep 23	72578.84
Sep 23	74366.5
Sep 23	75439.09
Aug 23	73508.43
Aug 23	74795.54
Aug 23	74151.98
Aug 23	74151.98
Jul 23	74366.5
Jul 23	74438.01
Jul 23	75224.57
Jul 23	74080.48
Jun 23	73865.96
Jun 23	73651.44
Jun 23	73651.44
Jun 23	73508.43
Jun 23	73579.93
May 23	73222.4
May 23	74294.99
May 23	73007.88
May 23	72793.36
Apr 23	72793.36
Apr 23	72793.36
Apr 23	72936.37
Apr 23	72578.84
Mar 23	72435.83
Mar 23	72864.87
Mar 23	72435.83
Mar 23	72507.34
Mar 23	72364.32
Feb 23	72435.83
Feb 23	72149.81
Feb 23	72006.79
Feb 23	72006.79
Jan 23	71863.78
Jan 23	71792.27
Jan 23	71577.76
Jan 23	71863.78

EV/EBITDA

NKGN EV/EBITDA by year
Period	EV/EBITDA
Sep 26	1.78
Sep 26	1.78
Aug 26	1.78
Aug 26	1.78
Aug 26	1.78
Aug 26	1.78
Jul 26	1.79
Jul 26	1.85
Jul 26	1.85
Jul 26	1.85
Jul 26	1.85
Jun 26	1.85
Jun 26	1.85
Jun 26	1.85
Jun 26	1.85
May 26	1.85
May 26	1.85
May 26	1.85
May 26	1.88
May 26	1.85
Apr 26	1.85
Apr 26	1.85
Apr 26	1.85
Apr 26	1.85
Mar 26	1.85
Mar 26	1.97
Mar 26	1.85
Mar 26	2.04
Feb 26	1.85
Feb 26	1.85
Feb 26	1.85
Feb 26	1.85
Jan 26	1.85
Jan 26	1.85
Jan 26	1.32
Jan 26	1.32
Jan 26	1.1
Dec 25	1.21
Dec 25	1.1
Dec 25	0.81
Dec 25	0.81
Nov 25	0.79
Nov 25	0.46
Nov 25	0.46
Nov 25	0.44
Oct 25	0.44
Oct 25	0.44
Oct 25	0.44
Oct 25	0.04

Price to Book

NKGN Price to Book by year
Period	Price to Book
Dec 23	0.85
Dec 23	1.04
Dec 23	1.05
Dec 23	1.05
Nov 23	0.91
Nov 23	0.87
Nov 23	0.91
Nov 23	0.95
Oct 23	1.09
Oct 23	0.93
Oct 23	0.93
Oct 23	1.09
Sep 23	2.57
Sep 23	1.21
Sep 23	1.29
Sep 23	1.32
Sep 23	1.34
Aug 23	1.3
Aug 23	1.32
Aug 23	1.31
Aug 23	1.31
Jul 23	1.32
Jul 23	1.32
Jul 23	1.33
Jul 23	1.31
Jun 23	1.31
Jun 23	141.37
Jun 23	141.37
Jun 23	141.09
Jun 23	141.23
May 23	140.54
May 23	142.6
May 23	140.13
May 23	139.72
Apr 23	139.72
Apr 23	139.72
Apr 23	139.99
Apr 23	139.31
Mar 23	139.03
Mar 23	1.3
Mar 23	1.29
Mar 23	1.29
Mar 23	1.29
Feb 23	1.29
Feb 23	1.29
Feb 23	1.28
Feb 23	1.28
Jan 23	1.28
Jan 23	1.28
Jan 23	1.28
Jan 23	1.28
Dec 22	1.27
Dec 22	1.27
Dec 22	1.27
Dec 22	1.27
Dec 22	1.27
Nov 22	1.27
Nov 22	1.27
Nov 22	1.26
Nov 22	1.26
Oct 22	1.26
Oct 22	1.25
Oct 22	1.25
Oct 22	1.25
Sep 22	1.25
Sep 22	1.29
Sep 22	1.29
Sep 22	1.29
Sep 22	1.28
Aug 22	1.28
Aug 22	1.29
Aug 22	1.29
Aug 22	1.29
Jul 22	1.29
Jul 22	1.29
Jul 22	1.29
Jul 22	1.29
Jul 22	1.28
Jun 22	1.3
Jun 22	1.3
Jun 22	1.3
Jun 22	1.3
May 22	1.29
May 22	1.29
May 22	1.29
May 22	1.3
Apr 22	1.3
Apr 22	1.3
Apr 22	1.3
Apr 22	1.3
Apr 22	1.3
Mar 22	1.28
Mar 22	1.28
Mar 22	1.28
Mar 22	1.28
Feb 22	1.29
Feb 22	1.29
Feb 22	1.29
Feb 22	1.28
Jan 22	1.28

No video analysis for this stock yet. Request one from our team.

News: NKGN

globenewswire.com · 10 Sep 2026

NKGen Biotech to Present on Potential of Troculeucel in Neurodegenerative Diseases at Biologics Manufacturing Korea 2026

SANTA ANA, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that NKGen Chairman and Chief Executive Officer Paul Y. Song, M.D., will present on the potential of troculeucel, the Company's lead investigational program, for the treatment of neurodegenerative diseases at Biologics Manufacturing Korea 2026, taking place September 17-18, 2026, in Incheon, South Korea.

globenewswire.com · 2 Jul 2026

NKGen Biotech to Present at the 2026 BIOCHINA Global Forum on Troculeucel's Potential in Alzheimer's Disease and Other Neurodegenerative Conditions

SANTA ANA, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that NKGen Chairman and Chief Executive Officer Paul Y. Song, M.D., will present on the Company's lead investigational program, troculeucel, at the 2026 BIOCHINA Global Forum, taking place July 9–10, 2026, in Seoul, South Korea.

globenewswire.com · 2 Jul 2026

NKGen Biotech to Present at the 2026 BIOCHINA Global Forum on Troculeucel’s Potential in Alzheimer’s Disease and Other Neurodegenerative Conditions

SANTA ANA, Calif. , July 02, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced that NKGen Chairman and Chief Executive Officer Paul Y.